Solvonis Therapeutics CEO on transformational first half, SVN-001 trial and licensing plans

Solvonis Therapeutics PLC (LSE:SVNS) Anthony Tennyson talked with Proactive's Stephen Gunnion about the company’s progress following its acquisition of Awakn Life Sciences and the advancement of its lead programs targeting central nervous system (CNS) disorders. Tennyson outlined how the acquisition strengthens Solvonis’s pipeline, bringing late clinical-stage assets in alcohol use disorder and psychiatry, specifically a joint venture for post-traumatic stress disorder. “With the acquisition of Awakn we're able to acquire linked clinical stage programs within addiction for alcohol use disorder and then acquire the full joint venture program... in Psychiatry for post-traumatic stress disorder,” he said. The company’s lead program, SVN-001, is currently in a Phase 3 trial in partnership with the University of Exeter and the UK Department of Health. Recruitment began in July 2024, with results expected in late 2027 or early 2028. Solvonis is in licensing discussions with several pharmaceutical firms for this asset. Tennyson also provided an update on SVN-002, which targets the US market by repurposing J&J’s SPRAVATO for alcohol use disorder. The FDA has agreed to a regulatory path that could bypass early-stage trials, significantly reducing costs. Key 2025 milestones include: progressing licensing for SVN-001, establishing a scientific bridge for SVN-002, and declaring a lead candidate for SVN-SDN14. For more videos like this, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and hit the notification bell to stay updated. #Solvonis #AnthonyTennyson #AlcoholUseDisorder #SVN001 #SVN002 #CentralNervousSystem #BiotechNews #CNSDisorders #DrugDevelopment #PTSDTreatment #PharmaLicensing #SPRAVATO #AwaknLifeSciences #proactiveinvestors

Light Science Technologies Holdings PLC (AIM:LST) CEO Simon Deacon talked with Proactive's Stephen Gunnion about the company’s progress in its Passive Fire Protection (PFP) division, highlighting the growth opportunities ahead. Deacon explained the importance of recently receiving the BS 8670 accreditation from Construction Online, which he described as “very significant” for the business. He noted that Construction Online was originally a government department and has been supporting thousands of businesses across Europe for more than 20 years in compliance and supply chain management. According to Deacon, the new accreditation is designed to “streamline the supply pre-qualification process and will really help unblock the delays across the construction industry and supply chain.” Deacon said the accreditation will further validate Light Science Technologies’ expertise across safety, leadership, risk management, and fire and life protection. He also discussed the company’s pipeline, which has grown to around £28 million. Recent orders worth approximately £0.5 million have been secured across the UK, covering projects in schools, hotels, social housing, and more. Looking ahead, Deacon said both the PFP and AgTech divisions are expected to be the strongest revenue generators, with net profit anticipated for the group in 2026 as backlogs clear. For more interviews and updates, visit Proactive’s YouTube channel. Don’t forget to give this video a like, subscribe, and enable notifications for future content. #LightScienceTechnologies #PassiveFireProtection #AgTech #ConstructionIndustry #FireSafety #UKBusiness #BuildingSafety #SupplyChain #RevenueGrowth #ProactiveInvestors

EMV Capital (AIM:EMVC) CEO Dr Ilian Iliev talked with Proactive's Stephen Gunnion about the company's evolving strategy, recent investments, and focus areas following its growth to over $100 million in assets under management. Iliev noted the company has expanded from 8 to over 70 portfolio companies since its merger with NetScientific five years ago. EMV Capital continues to target deep tech and life sciences sectors, underpinned by a capital-efficient investment model. He outlined how the business is managing liquidity through diverse revenue streams and selective secondary disposals. “The core of what we're doing is we're trying to get to a point where we're covering our ongoing costs from ongoing, cash resources,” Iliev explained. A key topic was EMV Capital’s acquisition of Destiny Pharma’s IP and clinical assets. Iliev described the deal as part of a broader strategy to address antimicrobial resistance. The company implemented a venture build program to grow the value of the asset at no cash cost, adding £0.5 million of direct value to its balance sheet. He also discussed Martlet Capital’s recent 2.5x return, which he said validated EMV’s dual-playbook strategy: active venture building and minority co-investments. Looking ahead, Iliev pointed to promising growth from portfolio companies including a US-based remote patient monitoring business and Scandinavian deep tech recycling initiatives. For more interviews and updates, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe to the channel, and enable notifications for future content. #EMVCapital #IlianIliev #DestinyPharma #VentureCapital #LifeSciences #DeepTech #InvestmentStrategy #AIMStocks #ProactiveInvestors #MartletCapital #AntimicrobialResistance #PrivateEquity #HealthcareInnovation

Trust Stamp President Andrew Gowasack joined Steve Darling from Proactive to announce the rollout of the company’s proprietary biometric-binding technology, positioning it as the critical solution to systemic failures in age-verification laws that are increasingly collapsing under real-world pressures. As governments worldwide push for stronger online safety measures, existing age-verification systems have proven inadequate. According to Gowasack, most current solutions rely on weak proxies—such as verifying a device, browser, or IP address—and then pretending this equals verifying a person. These approaches create security loopholes that can be easily exploited, leaving companies exposed to both regulatory penalties and reputational harm. Trust Stamp’s newly launched solution, TrustedAge™, directly addresses these flaws. Unlike traditional systems—likened by Gowasack to a “paper ticket, easily copied or passed around”—TrustedAge functions as a biometric key permanently bound to a single user. A live biometric capture confirms that the rightful owner is present for every login session, rendering the credential useless to anyone else. The urgency for a viable solution is clear. Gowasack noted that recent challenges in the UK with VPN-based circumvention are a preview of the chaos heading to the United States, where more than two dozen states are rolling out legislation mandating age verification. Companies face potential fines of up to $10,000 per violation, creating what Gowasack called a “compliance nightmare.” Trust Stamp’s technology offers a ready-to-deploy answer. After a one-time verification, the credential is permanently bound to the individual. Subsequent access requires only a quick, live selfie check—without storing sensitive biometric data. This ensures that the age credential is non-transferable, immune to theft or sharing, and closes compliance loopholes that leave companies vulnerable to both legal and financial risk. With TrustedAge, Trust Stamp positions itself at the forefront of solving one of the most urgent challenges in digital safety: enforcing age verification in a way that works, scales, and protects privacy. #proactiveinvestors #truststamp #nasdaq #idai #IdentityTech #DigitalIdentity #Fintech #GhanaID #SouthKoreaStartup #AsiaExpansion #KStartupChallenge #FinancialServices #Biometrics #TechExpansion #ProactiveInvestors #AndrewGowasack

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce that the company has received encouraging feedback from its recent Type C meeting with the U.S. Food and Drug Administration (FDA) regarding the clinical development pathway of its innovative microneedle-based therapy, Skinject™ (D-MNA), for the treatment of basal cell carcinoma (BCC). The Type C meeting focused on reviewing key elements of the protocol, including study design, endpoints, and patient population definitions for upcoming clinical trials. According to Dr. Bokhari, the FDA provided clarity and alignment on several critical points. Specifically, the agency indicated that a relative bioavailability study with D-MNA, administered under certain conditions, could serve as a basis for establishing a regulatory bridge while addressing bioavailability requirements for the product. Importantly, the FDA offered constructive and supportive guidance on multiple aspects of the proposed development program, including the appropriate primary endpoint for the next clinical study. The company must define the patient population, such as tumor size limits, lesion location restrictions, and histological confirmation requirements and design a randomized, double-blind, placebo-controlled trial to demonstrate efficacy in treating BCC. This regulatory clarity is expected to further strengthen Medicus Pharma’s ongoing clinical program. The company is currently conducting its Phase 2 trial across nine clinical sites in the United States. Patient randomization began in August 2024. In March 2025, Medicus Pharma announced results from an interim analysis of the Phase 2 study, showing a positively trending clinical clearance rate exceeding 60%. The interim data, based on more than half of the targeted 60 patients randomized at the time, were highly encouraging, although final results may vary once the study is fully completed. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #UAEHealth #NonInvasiveTherapy #Doxorubicin #ClinicalTrials #HealthcareInnovation

EnWave Corporation CEO Brent Charleton joined Steve Darling from Proactive to announce the signing of a new royalty-bearing, commercial license agreement with Solve Solutions, a Brazilian food company specializing in the production and sales of premium dried fruits, vegetables, and snack products. Solve Solutions serves both private label brands and consumer packaged goods manufacturers within Brazil and in international markets, making it a strong partner for EnWave’s global expansion strategy. As part of the agreement, Solve Solutions has also purchased one of EnWave’s 10kW Radiant Energy Vacuum (REV™) machines, which was previously leased under a Technology Evaluation and License Option Agreement. With this purchase, the company will now hold an exclusive license to use EnWave’s patented REV™ technology for drying select fruits, vegetables, and cheese products within Brazil. Under the terms of the deal, Solve Solutions will pay EnWave a royalty structure in line with other existing licensees. In addition, Solve Solutions is required to purchase a large-scale REV™ machine within six months of the commercial license’s effective date in order to maintain exclusivity, as well as remit minimum royalty payments on an ongoing basis. Charleton emphasized that EnWave intends to work closely with Solve Solutions to support product development and ensure the successful commercialization of premium dried food products in Brazil and beyond. By leveraging REV™ technology, Solve Solutions will be able to deliver shelf-stable, nutrient-rich products that appeal to health-conscious consumers while differentiating itself in a competitive global food marketplace. #proactiveinvestors #enwavecorporation #tsxv #enw #DehydrationTech #VacuumMicrowave #RoyaltyBusinessModel #BluechipClients #FoodTech #BusinessNews #Investing #RadiantEnergyVacuum #Agritech #Procescir #DehydrationTechnology #FoodInnovation #SupplyAgreement #InvestmentNews #ProactiveInvestors #microdried

American Resources Corp CEO Mark Jensen joined Steve Darling to announce a major long-term offtake partnership with POSCO International America Corp, a global leader in steel, magnetic materials, and advanced industrial solutions. The collaboration will unite ReElement’s cutting-edge chromatographic separation and purification platform with POSCO’s deep expertise in materials science, large-scale deployment, and its extensive relationships across the global automotive and industrial supply chains. Together, the companies will work to establish a scalable, secure, and sustainable supply chain for high-purity rare earth elements, which are indispensable to defense, clean energy, electric vehicles, advanced semiconductors, and emerging AI-driven technologies. Jensen explained that the agreement reflects both companies’ long-term commitment to developing resilient and transparent rare earth supply chains that meet the surging demand for critical minerals. As part of the partnership, ReElement and POSCO will form a joint taskforce dedicated to securing diverse global feedstock streams—including mixed rare earth concentrate, magnet manufacturing waste, and end-of-life scrap magnets—to ensure a reliable input pipeline for purification and refining. The offtake agreement includes an initial targeted supply of purified, separated rare earth oxides—specifically dysprosium, yttrium, terbium, and neodymium-praseodymium. The deal anticipates scaling production to over 3,000 metric tons through 2030, representing a transformative step toward meeting the world’s growing demand for magnet-grade rare earth elements. Beyond its commercial significance, the partnership also reinforces the strategic alliance between the United States and the Republic of Korea, aligning with global efforts to reduce dependency on limited and politically sensitive supply sources. By securing stable access to rare earths, this initiative directly supports national defense readiness, clean energy independence, and the advancement of next-generation technologies that underpin modern economies. #proactiveinvestors #americanresourcescorporation #nasdaq #arec #SustainableMining, #MineralRefining, #RecyclingInnovation, #CriticalMinerals, #RareEarthRecycling, #EVRecycling, #BatteryRecycling, #princialminerals #adamjohnson #RareEarths #EWasteRecycling #ReElement #CriticalMinerals #SustainableTech #MagnetRecycling #TechInnovation #GreenSupplyChain #ElectrifiedMaterials

Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler talked with Proactive's Stephen Gunnion about the company’s presence at ECTRIMS - the world’s largest conference focused on multiple sclerosis research and treatment - including the oral presentation and the late-breaking poster on its phase 2 CALLIPER trial results of vidofludimus calcium in progressive multiple sclerosis (MS). Muehler explained that the CALLIPER trial demonstrated a medically relevant signal for prevention of disability progression in both primary progressive MS (PPMS) and non-active secondary progressive MS (SPMS) populations. He highlighted that unlike most approved therapies, the trial results were not driven by residual inflammatory activity, but instead pointed to a potential neuroprotective effect through Nurr1 activation. “CALLIPER really showed a medically relevant signal for disability … it was a very consistent signal in this trial,” he said. He added that vidofludimus calcium showed a 2.8 times increase in disability improvement events compared with placebo and maintained a strong safety and tolerability profile with no new safety signals. Beyond CALLIPER, Immunic also presented three additional posters, including phase 2 long-term extension data in relapsing-remitting MS, showing that more than 90% of patients remained free from disability worsening after over three years of treatment. The company also shared new preclinical findings that further support vidofludimus calcium’s neuroprotective mechanism. Looking ahead, Muehler said regulatory discussions for a potential phase 3 trial in progressive MS are ongoing, while the next major milestone will be from the fully enrolled ENSURE phase 3 trials in relapsing MS, which are expected to deliver results in 2026. For more videos, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to our channel, and enable notifications for future updates. #Immunic #MultipleSclerosis #MSResearch #ECTRIMS2025 #ClinicalTrials #ProgressiveMS #RelapsingMS #VidofludimusCalcium #BiotechNews #Neuroprotection

Coinsilium Group Limited (AQSE:COIN, OTCQB:CINGF) CEO Eddy Travia and CFO Ben Proffitt talked with Proactive's Stephen Gunnion about the company’s interim results, treasury strategy and future outlook. Proffitt outlined the financial transformation driven by the launch of Forza Bitcoin, which raised approximately £17 million over the summer. Around 182 Bitcoin have now been added to the company’s treasury, leading to a significant rise in digital assets on the balance sheet. “Our Bitcoin value on the balance sheet moved from around £0.5 million to £6 million,” Proffitt stated, with cash reserves also increasing from £400,000 to £3.5 million. Travia said the Bitcoin treasury forms a foundational asset base but clarified that Coinsilium remains fundamentally a blockchain venture builder and investor. He noted that many of the company’s investments are held at cost due to their early-stage nature, but expects token launches to begin unlocking value. On this point, Proffitt discussed the Yellow Network’s upcoming $YELLOW token launch. Once live, the tokens will provide market-based valuations, enabling Coinsilium to reflect fair value in its portfolio. Looking ahead, Travia highlighted three major trends for 2026: the tokenisation of real-world assets, greater adoption of stablecoins, and evolving regulations opening the door to broader crypto adoption. “AI will play a role in the automation of crypto trading,” he added. For more videos like this, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and enable notifications so you never miss an update. # Coinsilium #BitcoinTreasury #ForzaBitcoin #YellowToken #CryptoInvestment #BlockchainVenture #Stablecoins #Tokenisation #CryptoTrading #RealWorldAssets #CryptoPortfolio #DigitalAssets #CryptoRegulation #Layer3Technology #ProactiveInvestors

EnergyPathways PLC (AIM:EPP) CEO Ben Clube talked with Proactive's Stephen Gunnion about the UK government’s designation of the company’s flagship MESH project as “nationally significant” — a major milestone under the Planning Act 2008. Clube explained that this classification helps streamline the planning and approval process, accelerating the project’s timeline with a view to being operational by 2030. The MESH project is central to the UK’s Clean Power 2030 goals, offering both long-duration energy storage and low-cost hydrogen production. Clube emphasised that “we think we can produce hydrogen at the lowest cost relative to two other technologies available to the UK market.” EnergyPathways has secured key partnerships with Siemens Energy, Costain, Zenith Energy, Hazar Group, and KBR Inc., each contributing to the integrated clean energy system — including compressed air energy storage and methane pyrolysis hydrogen production. Siemens is a core technology partner for energy storage, while Hazar and KBR support hydrogen development. Clube also discussed recent capital raised from investors and directors, confirming that the company has now entered the FEED (Front-End Engineering Design) stage. “There’s a lot of demand, we think, to backing the company through FEED and through the development cycle,” he added. The company expects several upcoming milestones as it navigates the Planning Act process and advances project approvals. For more interviews like this, visit Proactive's YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications for updates. #EnergyPathways #HydrogenProduction #CleanEnergyUK #MESHProject #BenClube #EnergyStorage #SiemensEnergy #MethanePyrolysis #NetZeroUK #FEEDstage #WindCurtailment #CompressedAirStorage #ProactiveInvestors #CleanPower2030